<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791565</url>
  </required_header>
  <id_info>
    <org_study_id>219430</org_study_id>
    <nct_id>NCT05791565</nct_id>
  </id_info>
  <brief_title>Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants</brief_title>
  <official_title>A Single Dose Two-way Cross-over Study in Healthy Participants to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers Containing Propellants HFA-152a and HFA-134a</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to compare the PK of salbutamol administered via metered dose&#xD;
      inhalers (MDI) containing propellants 1,1-difluroethane (HFA-152a) and&#xD;
      1,1,1,2-tetrafluoroethane (HFA-134a) in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2023</start_date>
  <completion_date type="Anticipated">May 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a 2-way cross-over study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This will be a double-blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) up to 30 minutes post-dose (AUC[0-30 minute]) of salbutamol</measure>
    <time_frame>Pre-dose and at 3, 5, 10, 15, 20 and 30 minutes post-dose on Days 1 and 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to infinity (AUC[0-inf]) of salbutamol</measure>
    <time_frame>Up to Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to time t (AUC[0-t]) of salbutamol</measure>
    <time_frame>Up to Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of salbutamol</measure>
    <time_frame>Up to Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of salbutamol</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal phase half-life (t1/2) of salbutamol</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum serum potassium level following administration of salbutamol</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted mean (0-4 hours) serum potassium level following administration of salbutamol</measure>
    <time_frame>Pre-dose and at 15 minutes, 30 minutes, 1, 1.5, 2 and 4 hours post-dose on Days 1 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum heart rate following administration of Salbutamol</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted mean (0-4 hours) heart rate following administration of Salbutamol</measure>
    <time_frame>Pre-dose and at 15 minutes, 30 minutes, 1, 1.5, 2 and 4 hours post-dose on Days 1 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum corrected QT (QTc) interval following administration of Salbutamol</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted mean (0-4 hours) QTc interval following administration of Salbutamol</measure>
    <time_frame>Pre-dose and at 15 minutes, 30 minutes, 1, 1.5, 2 and 4 hours post-dose on Days 1 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with non-serious adverse events and serious adverse events</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of Electrocardiogram (ECG) parameters: PR interval, QRS duration, QT interval and corrected QT (QTc) interval (Milliseconds)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ECG parameters: PR interval, QRS duration, QT interval and QTc interval (Milliseconds)</measure>
    <time_frame>Baseline and up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of ECG parameter: Heart rate (Beats per minute)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ECG parameters: Heart rate (Beats per minute)</measure>
    <time_frame>Baseline and up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet count (Giga cells per liter)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of hematology parameter: Red blood cell (RBC) count (Trillion cells per liter)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of hematology parameter: Mean corpuscular hemoglobin (MCH) (Picograms)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of hematology parameter: Percentage of reticulocytes (Percentage of reticulocytes)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of hematology parameter: Hemoglobin (Grams per Liter)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of hematology parameter: Hematocrit (Proportion of red blood cells in blood)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of clinical chemistry parameters: Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate aminotransferase (AST) and Creatine Phosphokinase (CPK) (International units per Liter)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of clinical chemistry parameters: direct bilirubin, total bilirubin and Creatinine (Micromoles per liter)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of clinical chemistry parameter: Total protein (Grams per liter)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values for Chemistry Parameters: Glucose, Calcium, Sodium, Potassium, Blood Urea Nitrogen (Millimoles per liter)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal urinalysis parameters by Dipstick Method</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of diastolic blood pressure (DBP) and systolic blood pressure (SBP) (Millimeters of mercury [mmHg])</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of pulse rate (Beats per minute)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Salbutamol HFA-152a MDI followed by Salbutamol HFA-134a MDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Salbutamol HFA-152a MDI in treatment period 1 followed by Salbutamol HFA-134a MDI in treatment period 2. There will be a minimum washout period of 72 hours between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salbutamol HFA-134a MDI followed by Salbutamol HFA-152a MDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Salbutamol HFA-134a MDI in treatment period 1 followed by Salbutamol HFA-152a MDI in treatment period 2. There will be a minimum washout period of 72 hours between each treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol HFA-152a</intervention_name>
    <description>Salbutamol HFA-152a will be administered.</description>
    <arm_group_label>Salbutamol HFA-134a MDI followed by Salbutamol HFA-152a MDI</arm_group_label>
    <arm_group_label>Salbutamol HFA-152a MDI followed by Salbutamol HFA-134a MDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol HFA-134a</intervention_name>
    <description>Salbutamol HFA-134a will be administered.</description>
    <arm_group_label>Salbutamol HFA-134a MDI followed by Salbutamol HFA-152a MDI</arm_group_label>
    <arm_group_label>Salbutamol HFA-152a MDI followed by Salbutamol HFA-134a MDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 55 years, inclusive, at screening&#xD;
&#xD;
          -  Body mass index 18.0 to 30.0 kilograms per meter square (kg/m^2), inclusive, at&#xD;
             screening&#xD;
&#xD;
          -  Weight: greater than or equal to (&gt;=)50 kg&#xD;
&#xD;
          -  At screening, females must not be pregnant or lactating, or of non-childbearing&#xD;
             potential&#xD;
&#xD;
          -  Female participants of childbearing potential who have a fertile male sexual partner&#xD;
             must agree to use adequate contraception&#xD;
&#xD;
          -  Male participants, if not surgically sterilized, must agree to use adequate&#xD;
             contraception&#xD;
&#xD;
          -  Good physical and mental health on the basis of medical history, physical examination,&#xD;
             clinical laboratory, electrocardiogram, and vital signs, as judged by the investigator&#xD;
&#xD;
          -  Willing and able to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,&#xD;
             endocrine, hematologic, or neurological disorders capable of significantly altering&#xD;
             the absorption, metabolism, or elimination of drugs; constituting a risk when taking&#xD;
             the study intervention or interfering with the interpretation of data&#xD;
&#xD;
          -  History or presence of any form of asthma, including childhood asthma and exercise&#xD;
             induced asthma&#xD;
&#xD;
          -  Current enrollment or past participation in this clinical study&#xD;
&#xD;
          -  Participants with clinically significant abnormalities&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen or a history (or suspected history) of&#xD;
             alcohol misuse or substance abuse&#xD;
&#xD;
          -  Positive nasopharyngeal polymerase chain reaction test for severe acute respiratory&#xD;
             syndrome-corona virus type 2 (SARS-CoV-2) on Day -1 or any known close contact with a&#xD;
             person who tested positive for SARS-CoV-2 or with a coronavirus disease 2019&#xD;
             participant within 2 weeks prior to admission&#xD;
&#xD;
          -  Impairment which would prevent the correct and consistent use of an MDI, as determined&#xD;
             by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9728</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <investigator>
      <last_name>Salah Hadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>April 21, 2023</last_update_submitted>
  <last_update_submitted_qc>April 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cross-over</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Salbutamol</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norflurane</mesh_term>
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.</ipd_time_frame>
    <ipd_access_criteria>Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.</ipd_access_criteria>
    <ipd_url>https://www.gsk.com/en-gb/innovation/trials/data-transparency/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

